Autolus Q3 Revenue Jumps 95% as AUCATZYL Tops $41M

Autolus Therapeutics plc (Nasdaq: AUTL) reported third quarter 2026 net product revenue of $41.2 million for its CAR T therapy AUCATZYL on November 10, 2026, a 95% increase from $21.1 million in the same quarter a year earlier. Gross margin reached 57%, up from 55% in the second quarter and a negative gross margin in the prior-year period. The London- and Gaithersburg-based company said it now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of its prior $150 million guidance.

Context — why the AUCATZYL revenue trajectory matters now

The company's prior guidance had pointed to full-year 2026 AUCATZYL revenue reaching the upper end of $150 million, and management now says results should land at or above that figure. The revision follows a quarter in which product revenue grew nearly twice over, driven by demand inside existing authorized treatment centers and expansion into new ones, with a contribution from UK sales. The report does not break out the UK share of the total.

The comparable that anchors the quarter is the prior-year period, when Autolus recorded a negative gross margin on $21.1 million in product revenue and $28.6 million in cost of sales. That gap has now closed and reversed. Cost of sales fell to $17.9 million in the third quarter of 2026 even as revenue roughly doubled, which the company attributes to lower manufacturing cost per batch, higher volumes, ongoing efficiency initiatives, and reduced inventory reserves and write-offs.

The catalyst chain runs through physician experience. Chief Executive Officer Dr. Christian Itin said the quarter was driven "primarily by growth within existing authorized treatment centers as physicians gain positive experience with the therapy," supported by real-world data reported through the ROCCA consortium. That is a commercial-adoption story rather than a new-approval story, and it matters because AUCATZYL's adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia indication is, in Itin's framing, the near-term value driver.

The macro backdrop is not a stated factor in the release. Autolus finances itself through product revenue and a credit facility rather than through rate-sensitive capital markets at this stage, and the report ties its cash position to the Perceptive facility rather than to broader conditions.

Data — what the numbers show

The revenue line is the headline: $41.2 million in the three months ended September 30, 2026, against $21.1 million a year earlier. For the nine months ended September 30, 2026, product revenue reached $113.1 million versus $51.0 million in the same period of 2025.

Metric (Q3)	2026	2025
Product revenue, net	$41.2M	$21.1M
Cost of sales	$17.9M	$28.6M
Gross margin	57%	negative
Loss from operations	$43.5M	$71.6M
Net loss	$55.1M	$79.1M
Net loss per share	$(0.21)	$(0.30)

Operating expenses moved in opposite directions. Research and development rose to $30.9 million from $27.9 million, which the company attributes to higher clinical manufacturing supply costs tied to development activity, partly offset by lower salary and employment costs. Selling, general and administrative expenses slipped to $35.9 million from $36.3 million, on lower salaries, employment-related costs and professional fees supporting US and UK commercialization.

Loss from operations narrowed to $43.5 million from $71.6 million. Net loss fell to $55.1 million from $79.1 million, and basic and diluted net loss per ordinary share improved to $(0.21) from $(0.30). Total other expenses, net, were $12.0 million in the quarter versus $7.0 million a year earlier.

Cash, cash equivalents and marketable securities totaled $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026. The company said the increase was primarily driven by net cash inflows from the senior secured note facility from Perceptive Advisors. Total shareholders' equity stood at $27.4 million, down from $178.1 million at December 31, 2025, while total liabilities rose to $495.7 million from $410.9 million.

Analysis — what it means for markets, sectors and tickers

The gross margin swing is the second-order story. A cell therapy moving from negative to 57% gross margin in four quarters changes the economics of every incremental patient treated, because cost per batch falls as volume rises and inventory write-offs shrink. For a commercial-stage biotech, that is the difference between a product that consumes cash per dose and one that contributes to it.

Autolus sits in the CD19-directed autologous CAR T space alongside larger commercial programs. The report does not name competitors or provide peer revenue figures, so no direct comparison is available from the disclosure. What the report does establish is that Autolus is funding operations from product revenue plus a credit facility rather than from equity issuance at the current share count, which the weighted-average share figure of roughly 266.2 million supports.

The risk case is manufacturing concentration. The margin improvement rests on cost per batch and volume, and any batch failure, capacity constraint, or inventory write-off reversal would pressure that 57% figure. The company also carries a meaningful liability stack relative to equity, with total liabilities of $495.7 million against shareholders' equity of $27.4 million at September 30, 2026 — a structure that gives creditors claims ahead of equity holders.

The pipeline carries its own timing risk. Autolus pushed its first progressive multiple sclerosis data presentation from an earlier window to the ECTRIMS Global meeting in October 2027, citing key opinion leader feedback that initial clinical activity and biomarker data across CAR T programs are encouraging but need longer follow-up to judge clinical benefit in progressive MS. That is a delay, and the company said it expects 12 months or more of follow-up for the initial 12 patients dosed, with data in up to 24 patients total by then.

Positioning is split between commercial execution and pipeline optionality. Investors underwriting the revenue line have the $41.2 million quarter and the raised full-year guidance; investors underwriting the pipeline are waiting on lupus, pediatric ALL, amyloidosis and MS readouts that mostly land in 2027 and 2028.

Outlook — what to watch next

Autolus said its current and projected cash, cash equivalents and marketable securities, including anticipated AUCATZYL revenue and $100 million in combined first and second tranches from the Perceptive credit facility, will fund operations into the second quarter of 2028. That runway is the binding constraint on the pipeline calendar.

The nearest catalyst is the ALARIC Phase 1 trial of AUTO8 in light-chain amyloidosis, with initial data expected at ASH in December 2026. Longer-term follow-up from the CARLYSLE trial in severe refractory systemic lupus erythematosus is being presented at the ACR Annual Meeting on November 10, 2026, covering up to 25 months of follow-up in adults and at least three months in adolescents.

The LUMINA Phase 2 study in refractory lupus nephritis continues enrolling across five countries, with data expected in 2028. Pediatric r/r B-ALL data from the Phase 2 portion of CATULUS are expected by year-end 2027. Progressive MS data from BOBCAT now point to October 2027. The FDA granted RMAT designation to obe-cel for SLE and LN on September 9, 2026.

The report names no price levels, moving averages, or technical thresholds, so none are cited here. The variable that matters most is whether quarterly product revenue continues to compound at or near the pace implied by the raised guidance.